Pfizer Inc vs Vanguard Value Index Fund ETF — how do they compare? Pfizer Inc trades at $24.91 (market cap $142.14B), while Vanguard Value Index Fund ETF trades at $219.51. The key difference: Pfizer Inc pays a 6.9% dividend while Vanguard Value Index Fund ETF pays none, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| PFE | VTV | |
|---|---|---|
Market Cap | $142.14B | — |
Volume | 29,869,932 | — |
Sector | Health | — |
52-Week High | $28.56 | $220.51 |
52-Week Low | $23.29 | $175.51 |
Enterprise Value | $192.80B | — |
Dividend Yield | 6.9% | — |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
VTV trades at $218.63, up 0.33% with a bullish technical outlook from moving averages. The ETF focuses on large-cap value stocks, offering diversification with low tech exposure and a 0.03% expense ratio. Recent news highlights its role as a stability play amid AI volatility, with a 16% YTD gain and a 27% one-year advance as of July 2026.
Outlook remains positive due to investor rotation into value stocks and Fed policy sensitivity. Risks include inflation-driven rate hikes and concentrated sector bets. Analyst sentiment favors VTV for defensive positioning, but macroeconomic shifts could challenge momentum.
Trailing returns across standard periods
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →